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Long noncoding RNAs (lncRNAs) have recently been found to play important roles in various cancer types. The elucidation
of genome-wide lncRNA expression patterns in metastatic nasopharyngeal carcinoma (NPC) could reveal novel mechanisms
underlying NPC carcinogenesis and progression. In this study, lncRNA expression profiling was performed on metastatic and
primary NPC tumors, and the differentially expressed lncRNAs between these samples were identified. A total of 33,045 lncRNA
probes were generated for ourmicroarray based on authoritative data sources, including RefSeq, UCSCKnowngenes, Ensembl, and
related literature. Using these probes, 8,088 lncRNAs were found to be significantly differentially expressed (≥2-fold). To identify
the prognostic value of these differentially expressed lncRNAs, four lncRNAs (LOC84740, ENST00000498296, AL359062, and
ENST00000438550) were selected; their expression levels were measured in an independent panel of 106 primary NPC samples via
QPCR. Among these lncRNAs, ENST00000438550 expression was demonstrated to be significantly correlated with NPC disease
progression. A survival analysis showed that a high expression level of ENST00000438550 was an independent indicator of disease
progression in NPC patients (𝑃 = 0.01). In summary, this study may provide novel diagnostic and prognostic biomarkers for NPC,
as well as a novel understanding of the mechanism underlying NPC metastasis and potential targets for future treatment.
1. Introduction
Nasopharyngeal carcinoma (NPC), a squamous cell carci-
noma that occurs in the epithelial lining of the nasopharynx,
displays a characteristic geographic and racial distribution
worldwide. NPC is a rare malignant tumor in Western
countries with an incidence of less than 1/100,000; however,
the incidence of NPC was reported to be greater than
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20/100,000 in southern China, especially among the Can-
tonese population living in the central region of Guangdong
Province [1, 2].The histological profile of NPC varies between
endemic and nonendemic areas. For example, the tumors
frommore than 95% of NPC patients in high-incidence areas
of China are undifferentiated nonkeratinizing carcinoma,
whereas those from patients of Western descent, such as
Caucasian, African-American, and Hispanic patients, are
predominantly keratinizing squamous cell carcinoma [3–5].
According to the WHO histological profile, NPC among
Chinese patients accounts for themajority of nonkeratinizing
carcinomas, including 55.9% of the differentiated nonker-
atinizing carcinomas and 58.0% of the undifferentiated
nonkeratinizing carcinomas. This difference is attributed to
the multifactorial etiology of NPC, which includes genetic
factors, viral infection, the environment, and dietary habits
[5–12].The cure rate of NPC has improved significantly since
the development of radiation technology and chemotherapy.
However, distant metastasis remains the primary reason
for treatment failure [3, 11, 13]. It is necessary to identify
the specific molecular mechanisms that contribute to the
pathogenesis and progression of NPC metastasis.
Recent studies suggest that noncoding RNAs (ncRNAs)
constitute a large proportion of genome-encoded transcripts
[14–16]. There is increasing evidence confirming that ncRNA
performs biological functions in both cis- and trans-gene
regulation, especially among higher eukaryotes [16–19]. Due
to their functional relevance, ncRNAs have been catego-
rized into housekeeping and regulatory ncRNAs [15]. Long
noncoding RNAs (lncRNAs with a length of more than
200 nucleotides) comprise a majority of regulatory ncRNAs
[15, 16, 20]. Many lncRNAs are highly conserved and are
involved in diverse cellular functions, such as epigenetic
regulation [21–23]. lncRNAs have been demonstrated to play
crucial roles in dosage compensation, genome imprinting,
X chromosome inactivation, chromatin modification, and
whole-genome rearrangement [17, 18, 21, 24, 25]. The dys-
regulated expression of lncRNAs has been identified in a
variety of diseases, including different types of cancer [26];
this observation suggests that aberrant lncRNA expression
may represent a major contributor to carcinogenesis and
cancer progression [17, 27]. For example, HOTAIR and
ANRIL act as cancer regulators in carcinogenesis and cancer
progression [17, 28]. HOTAIR expression levels increase with
clinical stage progression in NPC; NPC patients with high
HOTAIR levels have a poor prognosis for overall survival
[29]; metastasis-associated lung adenocarcinoma transcript
(MALAT-1), PANDA, and ncRNA-DHFR regulate DNA
damage, the cell cycle, alternative splicing, and tumor pro-
gression [30, 31]. Based on microarray analysis, the H19 gene
is strongly expressed in undifferentiated NPC. Furthermore,
H19 is highly expressed in an undifferentiated human NPC
cell line. H19 plays a role in the differentiation of humanNPC
cells and the transcriptional silencing of imprinted genes [32].
LINC00312, also named NAG7 (NPC-associated gene 7), is
a lincRNA expressed in the cytoplasm of nasopharyngeal
epithelial cells. LINC00312 is expressed in 51.4% of NPC
samples and 78.4%of noncancerous nasopharyngeal epithelia
samples (𝑃 < 0.001) [33]. Compared with noncancer-
ous nasopharyngeal epithelial tissues, LINC00312 is signif-
icantly downregulated in NPC tissues. LINC00312 could
be used as a biomarker for NPC metastasis, progression,
and prognosis. Based on rematching and reannotation of
the existing microarray datasets, five lncRNAs were selected
to validate the differential expression of lncRNAs in both
primary and recurrent nasopharyngeal carcinoma compared
with noncancerous nasopharyngeal epithelia [34]. However,
most of the differentially expressed lncRNAs have not been
functionally characterized. We suspect that some of these
lncRNAs play roles in NPC progression and that some are
candidate biomarkers for the diagnosis or prognosis of NPC.
The novel molecularmechanisms by which lncRNAs regulate
carcinogenesis and metastasis are expected to be elucidated.
In the present study, we performed lncRNA expression
profiling on metastatic and primary NPC tumors and identi-
fied differentially expressed lncRNAs that could show altered
expression prior to or during the invasion-metastasis process.
Further investigation validated that the expression level of the
lncRNA ENST00000438550 was an independent prognostic
marker in NPC patients.
2. Materials and Methods
2.1. Patients and Tissue Specimens. From July 2010 to Novem-
ber 2012, a total of 110 primary NPC samples and 3 metastatic
NPC samples with confirmed pathology were collected from
Sun Yat-Sen University Cancer Center. All of the samples
were excess discarded tissues from diagnostic procedures.
Three NPC metastatic tissue samples were collected via nee-
dle biopsy of bone metastatic sites of NPC patients. Among
the 110 primary NPC samples, 4 of them were randomly
selected for lncRNA microarray analysis. The remaining
106 primary NPC samples underwent QPCR. The tumor
tissues from each subject were snap-frozen in liquid nitrogen
immediately after biopsy. Written informed consent was
obtained from all patients. The research ethics committee of
Sun Yat-Sen University Cancer Center approved this study.
No patients had received therapy prior to biopsy. The TNM
classification of the patients was determined according to the
criteria of the American Joint Committee on Cancer (AJCC
7th edition).The detailed clinical information corresponding
to the seven NPC patient samples used for microarray anal-
ysis is presented in Table S01 in the Supplementary Material
available online at http://dx.doi.org/10.1155/2015/618924.
2.2. RNAExtraction. Total RNAwas extracted from 113 snap-
frozen samples using TRIzol reagent (Invitrogen) according
to the manufacturer’s protocol. The sample quality was
evaluated using a Nano Drop ND-1000 spectrophotometer
and standard denaturing agarose gel electrophoresis.
2.3. Microarray and Computational Analyses. Formicroarray
analysis, the previously prepared total RNA from each sample
was purified after rRNA removal (mRNA-ONLY Eukaryotic
mRNA Isolation Kit, Epicentre) and then amplified and
transcribed into fluorescent cRNA along the entire length of
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the transcripts without 3󸀠 bias utilizing a random priming
method. The labeled cRNAs were hybridized to the Human
lncRNA Array v2.0 (8 × 60K, Arraystar). After washing the
slides, the arrays were scanned using the Agilent Scanner
G2505C.
Agilent Feature Extraction software (version 11.0.1.1) was
used to analyze the acquired array images. Quantile nor-
malization and subsequent data processing were performed
using the GeneSpring GX v11.5.1 software package (Agilent
Technologies). After quantile normalization of the raw data,
lncRNAs inwhich all 7 samples displayed flags corresponding
to Present or Marginal (“All Targets Value”) were selected for
further data analysis. The differentially expressed lncRNAs
displaying statistical significance between the two groups
were identified via Volcano Plot filtering. Finally, hierarchi-
cal clustering was performed to elucidate the differentially
expressed lncRNA expression profile in the samples.
The experimental protocol was as follows: (1) RNA
extraction and RNA QC (described previously); (2) labeling
and hybridization (the Agilent Quick Amp Labeling Kit
was used for sample labeling and hybridization was per-
formed in Agilent Sure Hyb Hybridization Chambers); (3)
data collection and normalization; (4) further data analysis
(using Agilent Gene Spring GX v11.5.1 software); and (5)
lncRNA classification and subgroup analysis (using home-
made scripts). The microarray was performed by KangChen
Bio-tech, Shanghai, China.
2.4. Quantitative RT-PCR. Real-time PCR was performed
using a LightCycler 480 (Roche, Basel, Switzerland). The
reactions were performed in triplicate, and the relative
expression of lncRNAs (LOC84740, ENST00000498296,
AL359062, and ENST00000438550) was normalized to that
of the internal control GAPDH. The primer sequences are
presented in Supplementary Table S02.
2.5. Statistics. Statistical analyses were performed using SPSS
version 16.0. Receiver operating characteristic (ROC) curve
analysis was used to select the threshold expression levels
of the lncRNAs detected via QPCR for disease-free survival
(DFS). The survival curves were plotted using the Kaplan-
Meier method and were compared using the log-rank test.
A multivariate survival analysis was performed using a Cox
proportional hazards model (forward). The statistical tests
were two-sided, and 𝑃 < 0.05 was considered to be
significant.
3. Results
3.1. Overview of the lncRNA Expression Profiles. Using the
lncRNA expression profiles, differentially expressed lncR-
NAs were determined between the metastatic and primary
NPC tumor tissues. The differences in lncRNA expression
were evaluated by calculating the normalized fold-change in
lncRNA expression between the metastatic/primary tumor
(M/T) samples. The selection criterion was a fold-change
threshold of 2.0. A positive fold-change indicated upregula-
tion, whereas a negative fold-change indicated downregula-
tion. Log fold-change corresponded to the log2 value of the
absolute fold-change. Both the fold-change and the 𝑃 value
were normalized. Thousands of lncRNAs were found to be
differentially expressed between the metastatic and primary
NPC tumors according to UCSC-known gene, Ensemble,
RefSeq NR, H-invDB, NRED, RNAdb, lincRNA, RNAdb,
HOX cluster, misc RNA, UCR, and lncRNAdb.
A total of 33,045 lncRNA probes were used in our
lncRNA microarray. Up to 30,610 lncRNAs were detected
in all seven samples (Table S03). Thousands of lncRNAs
were found to be differentially expressed, and samples in the
same group shared many differentially expressed lncRNAs
(Figure 1, Table 1, Table S04). A total of 8,088 lncRNAs
were identified to be significantly differentially expressed
(≥2-fold) between the metastatic and primary NPC tumors
(Table 1, Table S04). Among these, 3,778 lncRNAs were
found to be consistently upregulated; 4,310 lncRNAs were
downregulated. Additionally, H19 was found to be 2.2-fold
upregulated in the metastatic tissue, which could be related
tometastasis (Figure 1, Tables S03-S04). CR620154 (log2 fold-
change M/T = 94.02) was the most significantly upregulated
lncRNA, and TUBA4B (log2 fold-change M/T = −1,364.72)
was the most significantly downregulated lncRNA (Table 2).
3.2. lncRNA Classification and Subgroup Analysis. According
to the function and locus of each lncRNA and its association
with protein-encoding RNA, Gibb et al. separated lncRNAs
into several categories, such as long intronic ncRNAs, anti-
sense RNAs, and promoter-associated long RNAs [35]. In
our microarray study, the lncRNAs were classified into four
subgroups: enhancer lncRNAs acting on a nearby coding
gene, HOX cluster, lncRNAs near a coding gene, and Rinn
lincRNAs [23, 36–38]. The expression levels of the lncRNAs
in these subgroups were different between the metastatic and
primary NPC tumors (Figure 2, Table 1).
In our study, we found that 477 transcribed regions
in HOX loci; of these, 257 were ncRNAs and 220 were
HOX coding transcripts (Table S05). In the four randomly
paired groups, the number of differentially expressed lncR-
NAs differed, but several lncRNAs displayed similar changes
in expression. Compared with the NPC primary tumors,
70 lncRNAs were found to be differentially expressed in
metastatic tissues; 51 coding transcripts were differentially
expressed (Table S06, Figure 3(a)). According to the compar-
ative analysis of the four randomly paired groups, 33 lncRNAs
were upregulated and 37 lncRNAs were downregulated in
the metastatic NPC samples compared with the primary
NPC tumor samples (Figure 3(b)). Interestingly, HOTAIR,
a known regulatory lncRNA located at the HOX locus, was
among the 33 upregulated lncRNAs (Figure 3(c)). HOTAIR
has been demonstrated to be an oncogene to modulate the
metastasis of breast cancer and NPC [17, 39].
Rinn lincRNAs, a type of lincRNAs identified by Rinn,
were also detected in our study [23, 38]. A total of 4,199 Rinn
lincRNAs were detected in our microarray (Table S07). The
number of upregulated and downregulated Rinn lincRNAs
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Figure 1: The number of upregulated and downregulated lncRNAs. (a) Hierarchical clustering was performed based on “All Targets Value-
lncRNAs.”The results of hierarchical clustering revealed distinct lncRNA expression profiles between the samples. (b)Thousands of lncRNAs
were found to be significantly upregulated or downregulated in metastatic NPC tumors compared with primary NPC tumors in seven NPC
patients based on microarray analysis. The number of upregulated and downregulated lncRNAs varied between the seven patients. In the
four randomly paired M and T groups, downregulated lncRNAs were more common than upregulated lncRNAs. (c) H19 was found to be
upregulated in all metastatic samples (𝑃 < 0.001); the expression levels of H19 were 1.8- to 3-fold higher in the metastatic tumors than in the
primary tumors.
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Table 1: Summary of the microarray data for the metastatic and primary NPC tumors.
Gene type RNA expression Fold-change (𝑛) Differentially expressed RNAs (𝑛)
>20 10–20 2–10 Total
lncRNA Upregulated 65 191 3,522 3,778 8,088
Downregulated 198 225 3,887 4,310
Enhancer lncRNAs regulating a nearby
coding gene
Upregulated 4 5 94 103 462
Downregulated 17 20 322 359
HOX cluster Upregulated 15 5 51 71 121
Downregulated 1 3 46 50
lncRNAs regulating a nearby coding
gene
Upregulated 4 5 94 103 462
Downregulated 17 20 322 359
Rinn lincRNAs Upregulated 6 14 328 348 1,069
Downregulated 33 28 660 721
NPC: nasopharyngeal carcinoma; lncRNA: long noncoding RNA; lincRNA: long intergenic noncoding RNA.
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Figure 2: The number of upregulated and downregulated lncRNAs
in each subgroup. The lncRNAs were classified into four subgroups
based on microarray analysis, including enhancer lncRNAs regulat-
ing a nearby coding gene,HOXcluster, lincRNAs regulating a nearby
coding gene, and Rinn lincRNAs. The number of lncRNAs that
were consistently upregulated or downregulated in the metastatic
tumors compared with the primary tumors was calculated for each
subgroup.
varied between the seven patients. A total of 1,069 Rinn
lincRNAs were found to be differentially expressed between
the patient samples (Figure 4, Table S08). As shown in
Figure 4, the downregulation of the lncRNAs was more com-
mon than the upregulation. Among the four paired samples,
we found 348 lncRNAs that were consistently upregulated
and 721 lncRNAs that were consistently downregulated. The
consistently dysregulated lncRNAs in the four groups may
function as oncogenes or tumor suppressor genes; this merits
further investigation.
Enhancer lncRNAs acting on a nearby coding gene were
first found in human cell lines [37].Thepresent study revealed
an unanticipated role of this subgroup of lncRNAs in the
Table 2: A collection of significantly differentially expressed lncR-
NAs detected via microarray analysis in seven NPC patients.
Upregulated Downregulated
lncRNA
log2
fold-change
(M/T)
lncRNA
log2
fold-change
(M/T)
CR620154 94.02 TUBA4B 1,364.72
LOC84740 92.86 AK128150 1,120.20
nc-HOXB9-206 87.55 RP11-79C6.2 303.82
RP4-800M22.4 67.25 EFCAB10 274.84
RP11-450H5.1 65.75 RP11-1C1.7 208.11
RP11-429H5.1 64.15 RP11-275I14.4 206.67
CTC-327F10.5 62.57 CR607309 197.51
AK096329 58.19 RP1-20N18.4 196.02
AC079780.3 55.47 lincRNA-CDHR3 195.01
AK129524 53.04 BC041885 141.04
AL359062 50.10 lincRNA-TSPAN8 137.80
RP11-95M15.1 46.94 BC050410 131.80
RP11-455B3.1 45.48 RP4-539M6.14 130.89
RP11-188P8.2 41.74 IGKV 125.27
AC097523.2 41.72 AC013264.2 122.93
nc-HOXA11-86 41.48 CES4 120.27
RP11-600P1.1 38.72 CLLU1 108.35
LOC283392 33.97 TUBBP5 108.01
AK096314 33.87 RP11-128M1.1 105.58
AC116917.2 33.61 RP4-666F24.3 100.17
NPC: nasopharyngeal carcinoma;M:metastaticNPC tissue; T: primaryNPC
tissue.
False discovery rate (FDR) < 0.1%, 𝑃 < 0.01.
activation of critical development and differentiation regu-
lators. In this study, many enhancer lncRNAs were found to
display increased or decreased expression in M/T. Enhancer
lncRNA profiling contained the profiling data of all lncRNAs
displaying enhancer-like function (Table S09). A total of
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Figure 3: The number of differentially expressed lncRNAs at the HOX locus. (a) The transcripts at the HOX locus varied between the four
randomly paired M and T groups. A total of 70 lncRNAs were found to be differentially expressed in the metastatic tissues, and 51 coding
transcripts were differentially expressed. (b) Different numbers of lncRNAs were detected in the four randomly paired M and T groups. A
total of 33 lncRNAs at the HOX locus were found to be upregulated in all groups, and 37 lncRNAs were downregulated. (c) HOTAIR was
found to be upregulated in themetastatic tumor samples from all of the groups (𝑃 < 0.001); the expression levels of HOTAIR in themetastatic
tumors were 4- to 6-fold higher than those in the primary tumors.
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Figure 4: The number of differentially expressed Rinn lincRNAs. Rinn lincRNAs are a type of lincRNAs termed based on studies by Rinn.
A total of 4,199 Rinn lincRNAs were detected in our microarray analysis. The number of downregulated Rinn lincRNAs was greater than
the number of upregulated Rinn lincRNAs. According to the expression levels of all detected Rinn lincRNAs in metastatic and primary NPC
tumors, 348 of these lncRNAs displayed consistent upregulation and 721 of these lncRNAs displayed consistent downregulation in the four
randomly paired M and T groups.
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Table 3: The clinicopathological characteristics and their association with the expression levels of four lncRNAs (LOC84740,
ENST00000498296, AL359062, and ENST00000438550) in NPC patients.
LOC84740
(𝑛 = 105)
ENST00000498296
(𝑛 = 106)
AL359062
(𝑛 = 106)
ENST00000438550
(𝑛 = 106)
L H 𝑃 L H 𝑃 L H 𝑃 L H 𝑃
Age (years)
<50 53 14 0.81 25 43 0.54 34 34 0.23 12 56 0.06
≥50 29 9 17 21 14 24 13 25
Gender
Male 66 15 0.15 32 49 1.00 37 44 0.82 11 70 0.00
Female 15 8 9 15 10 14 14 10
Histological type
D 2 0 0.00 0 2 0.52 1 1 1.00 1 1 0.42
U 80 23 42 62 47 57 24 80
T classification
T1-2 7 0 0.34 4 3 0.43 5 2 0.24 1 6 1.00
T3-4 75 23 38 61 43 56 24 75
N classification
N0-1 51 16 0.63 26 41 0.84 28 39 0.42 15 52 0.81
N2-3 31 7 16 23 20 19 10 29
Distant metastasis
No 73 18 0.18 36 56 0.78 44 48 0.25 24 68 0.18
Yes 9 5 6 8 4 10 1 13
Local-regional relapse
No 74 21 1.00 40 56 0.31 45 51 0.34 25 71 0.11
Yes 8 2 2 8 3 7 0 10
Disease progression
No 65 17 0.58 34 49 0.64 41 42 0.16 24 59 0.01
Yes 17 6 8 15 7 16 1 22
L: low level; H: high level; 𝑃: 𝑃 value; D: differentiated nonkeratinized carcinoma; U: undifferentiated nonkeratinized carcinoma.
1,598 enhancer lncRNAs were detected, of which 468 were
differentially expressed.Thedifferentially expressed enhancer
lncRNAs and their nearby coding genes (distance < 300 kb)
are presented inTable S10. As shown in Figure 5, the enhancer
lncRNAs were located either upstream or downstream of the
coding genes. Someof the enhancer lncRNAs shared the same
change in expression with their nearby coding genes, while
the others displayed the opposite changes; this was helpful for
the identification of functional enhancer lncRNAs.
We performed a further analysis of the lincRNA profiles
to identify additional potential regulatory lncRNAs and
their target genes among the lincRNAs. The differentially
expressed lincRNAs and nearby coding gene pairs (distance
< 300 kb) are provided in Table S11 (𝑃 < 0.05).
3.3. Real-Time Quantitative PCR Validation. Based on this
microarray analysis and according to the baseline and fold-
change in the expression levels, four different lncRNA
members (LOC84740, ENST00000498296, AL359062, and
ENST00000438550) were selected to verify their expression
levels via QPCR. The results revealed strong consistency
among the QPCR results and the microarray data (Figures
6(a)-6(b)). Additionally, the expression levels of the four
lncRNAs (LOC84740, ENST00000498296, AL359062, and
ENST00000438550) were measured in an independent panel
of 106 primary NPC samples via QPCR; however, the sample
from one patient did not show expression of LOC84740
(Figure 6(c), Table 3). The clinicopathological characteris-
tics of these 106 patients and the associations between
these characteristics and the expression levels of LOC84740,
ENST00000498296, AL359062, and ENST00000438550 are
presented in Table 3. According to their respective ROC
curves, the fold-change cutoff points in the expression
thresholds for LOC84740, ENST00000498296, AL359062,
and ENST00000438550 were 5.54, 0.37, 3.76, and 0.43,
respectively. The expression levels of the lncRNAs were
categorized into high and low levels accordingly. A high
ENST00000438550 expression level was associated with dis-
ease progression among NPC patients (𝑃 = 0.01).
3.4. Prognosis of NPC Patients Displaying Differentially
Expressed lncRNAs. To further confirm the prognostic value
of these lncRNAs for NPC, the DFS of the four lncRNAs
was analyzed. Among them, only ENST00000438550 was a
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Figure 5: Expression levels of enhancer lncRNAs and their nearby coding genes based on genome relationship analysis. A total of 245
enhancer lncRNAs upstream of their nearby coding genes were differentially expressed; 58 of these enhancer lncRNAs were upregulated and
187 were downregulated. Additionally, 217 enhancer lncRNAs downstream of their nearby coding genes were differentially expressed; 45 of
these enhancer lncRNAs were upregulated and 172 were downregulated. Some of the nearby coding genes displayed consistent upregulation
or downregulation in concert with that of their corresponding enhancer lncRNAs, whereas other nearby coding genes displayed opposite
differences.
significant predictor of disease progression in NPC patients
(3-year DFS of 96% and 73% for the low and high level
groups, respectively, 𝑃 = 0.02, Figure 7). A multivari-
ate analysis was performed using the COX proportional
hazards model to analyze the prognostic values of age,
gender, T classification, N classification, and the expres-
sion levels of LOC84740, ENST00000498296, AL359062,
and ENST00000438550. The results revealed that only the
expression level of ENST00000438550 was an independent
prognostic indicator of disease progression in NPC patients
(Chi square = 6.64, 𝑃 = 0.01). These results suggested that
ENST00000438550 could serve as a prognostic marker in
NPC patients.
4. Discussion
The present study was the first to demonstrate that lncRNAs
are differentially expressed between metastatic and primary
NPC tumors.There have been no previous reports describing
lncRNA expression profiles of NPC samples that also per-
formed a differential expression analysis. Furthermore, this
study was the first to demonstrate that a high expression level
of ENST00000438550 is an independent indicator of disease
progression in NPC patients.
Epstein-Barr virus (EBV) plays very important roles
in the carcinogenesis of NPC. EBV exhibits tumorigenic
potential due to a unique set of latent genes. Latentmembrane
protein-1 (LMP1) is the principal oncogene, and its expression
level is a prognostic marker of NPC [40]. With the develop-
ment of microarray technology, novel potential therapeutic
targets as well as diagnostic and prognostic biomarkers have
been identified based on gene expression array analyses.
lncRNA expression array analysis has been used in oncology
studies in recent years. A variety of lncRNAs, including
ANRIL, MEG3 and HULC, either promote or suppress the
development of cancer [41–44]. Among these, XIST is a
well-known imprinted lncRNA that is abnormally expressed
in ovarian and breast cancers [45, 46]. MALAT-1 was the
first lncRNA that was found to be associated with high
metastatic potential and poor patient prognosis in non-small-
cell lung cancer patients [47].MALAT-1 is also upregulated in
other human cancers, such as breast cancer, prostate cancer,
colorectal cancer, liver cancer, and uterine cancer [48–51].
These findings imply an association between lncRNAs and
carcinogenesis.
The altered expression of many genes has been reported
to be associated with the development of NPC [52, 53].
HOTAIR, a lincRNA in the mammalian HOXC locus, was
the first lincRNA that was found to be systematically dys-
regulated during breast cancer progression via microarray
analysis [17]. Further evidence indicates that HOTAIR repro-
grams the chromatin state to promote cancer metastasis
and primary tumor growth in vivo [17]. HOTAIR has been
proposed as a putative biomarker for metastasis of human
malignant tumors, and it is a powerful predictor of even-
tual metastasis and death [17, 29]. HOTAIR is aberrantly
expressed in several carcinomas, including NPC [29, 39,
54–56]. HOTAIR is upregulated in cases of NPC at more
advanced clinical stage andwith increased lymphnode tumor
burden [29]. In our study, HOTAIR was also consistently
upregulated in metastatic samples, indicating that increased
HOTAIR expression is associated with the progression and
development of NPC. H19, another imprinted lncRNA gene
with high expression levels during vertebrate embryo devel-
opment, is downregulated in most tissues shortly after birth
[57]. Its loss of imprinting and aberrant expression has been
detected in various cancers and has been demonstrated to
play a key role in oncogenesis and tumor suppression [18,
32, 58–61]. H19 expression is induced by hypermethylation
of its promoter region. H19 is significantly upregulated in the
undifferentiated human NPC cell line CNE-2, but it is not
expressed in well-differentiated human HK1 NPC cells [32].
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Figure 6: Real-time quantitative PCR validation. (a) Raw data of the expression levels of the four lncRNAs (LOC84740, ENST00000498296,
AL359062, and ENST00000438550) based on microarray analysis. All four of these lncRNAs displayed a high basal expression level in
metastatic and primary NPC tumors, but their expression levels significantly differed between the two groups. ∗∗∗𝑃 < 0.001. (b) Validation of
the microarray data. All four lncRNAs (LOC84740, ENST00000498296, AL359062, and ENST00000438550) were differentially expressed in
the metastatic and primary NPC tumors based on microarray analysis, which was validated via QPCR using the same tissues. The validation
results of the four lncRNAs indicated that themicroarray data strongly correlatedwith theQPCR results. ∗∗∗𝑃 < 0.001 and ∗∗𝑃 < 0.01. (c)The
expression levels of four lncRNAs (LOC84740, ENST00000498296, AL359062, and ENST00000438550) were measured in an independent
panel of 106 primary NPC samples via QPCR. These lncRNAs displayed higher expression levels in NPC primary tumors with progression
than in those without progression. ∗𝑃 < 0.05.
Our study observed that H19 expression was upregulated in
metastaticNPC tumors comparedwith primaryNPC tumors;
this result suggests that H19 expression is related to NPC
progression.
lincRNA LINC00312 is significantly downregulated in
NPC tissues compared with noncancerous nasopharyngeal
epithelial tissues as assessed by a NPC tissue microarray [33].
However, we did not find LINC00312 in our differentially
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Figure 7: DFS. The expression level of ENST00000438550 correlated with disease progression in NPC patients; those displaying a
high ENST00000438550 expression level experienced a significantly shorter DFS (d). However, the expression levels of LOC84740,
ENST00000498296, and AL359062 were not correlated with the DFS of the NPC patients ((a)–(c)).
expressed lncRNAs. The expression of LINC00312 decreased
with NPC progression. In addition, only half of the NPC
samples express LINC00312, and the number of samples
used in our microarray study is limited. Five lncRNAs
(lnc-C22orf32-1, lnc-TLR4-1, lnc-BCL2L11-3, lnc-AL355149.1-
1, and lnc-ZNF674-1) were differentially expressed in NPC
compared with normal nasopharyngeal epithelial tissues
in the microarray data set GSE12452 [34]. Four of these
lncRNAs (lnc-C22orf32-1, lncTLR4-1, lnc-AL355149.1-1, and
lnc-ZNF674-1) demonstrated significant expression differ-
ences between primary NPC and normal nasopharyngeal
samples via QPCR. Only lnc-BCL2L11-3 was upregulated in
the recurrent NPC tissues compared with the paired normal
tissues. lnc-AL355149.1-1 and lnc-ZNF674-1 were downregu-
lated compared with primary NPC. Unfortunately, none of
the five lncRNAs were identified among the differentially
expressed lncRNAs based on our microarray data. Our
research focuses onNPCmetastasis, and the expression of the
five lncRNAs varied during carcinogenesis and recurrence.
Based on this microarray analysis and according to
the baseline and fold-change in the expression levels, four
lncRNAs (LOC84740, ENST00000498296, AL359062, and
ENST00000438550) were selected to validate the microarray
results and to evaluate their roles as biomarkers in NPC
patients. Consistent with the microarray results, the four
lncRNAs were differentially expressed based on QPCR. To
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further illustrate the relationship between these four lncRNAs
and NPC prognosis, we analyzed the expression levels of
these four lncRNAs via QPCR and evaluated their potential
values as prognostic indicators of NPC. We found that,
among these four lncRNAs, only ENST00000438550 was an
independent prognostic indicator of disease progression in
NPCpatients.The expression level of ENST00000438550was
negatively correlated with the prognosis of NPC patients;
this suggests that elucidating the role of ENST00000438550
in NPC progression may contribute to understanding of the
mechanism of NPC metastasis.
5. Conclusion
To the best of our knowledge, few differentially expressed
lncRNAs have been reported in NPC, and this is the
first report elucidating the lncRNA expression profiles of
metastatic and primary NPC tumor tissues. Further inves-
tigation is required in the search for additional functional
lncRNAs in NPC. This study has limitations, including the
limited sample number for microarray analysis, which was
partially due to the difficulty in conducting bone metastases
biopsies. In brief, our finding provides new insights into
understanding NPC. lncRNAs may underlie novel mech-
anisms of NPC and may represent potential targets for
NPC treatment and prognostic factors for NPC, which are
expected to be elucidated in the near future.
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